Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Pieris Pharmaceuticals, Inc. (PIRS)

1.02   0.02 (2%) 11-28 10:11
Open: 0.99 Pre. Close: 1
High: 1.02 Low: 0.98
Volume: 22,987 Market Cap: 76(M)

Technical analysis

as of: 2022-11-28 9:51:13 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.24     One year: 1.34
Support: Support1: 0.92    Support2: 0.76
Resistance: Resistance1: 1.06    Resistance2: 1.14
Pivot: 0.98
Moving Average: MA(5): 0.97     MA(20): 1
MA(100): 1.36     MA(250): 2.24
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 45.1     %D(3): 33
RSI: RSI(14): 45.4
52-week: High: 4.07  Low: 0.92
Average Vol(K): 3-Month: 160 (K)  10-Days: 186 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PIRS ] has closed below upper band by 48.8%. Bollinger Bands are 60% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.02 - 1.02 1.02 - 1.03
Low: 0.97 - 0.98 0.98 - 0.98
Close: 0.99 - 1 1 - 1.01

Company Description

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Headline News

Mon, 28 Nov 2022
Sasha Vezenkov named EuroLeague MVP of the Month - Eurohoops

Sun, 27 Nov 2022
55-73: Third win of the week - Real Madrid

Thu, 24 Nov 2022
Ali Gul Pir hilariously recreates the viral interview of 'Rabia' - Daily Pakistan Global

Sun, 20 Nov 2022
Sasha Vezenkov joins exclusive EuroLeague PIR list - Eurohoops

Tue, 15 Nov 2022
PIR announces winners of 4th Annual .ORG Impact Awards - Domain Name Wire

Sun, 06 Nov 2022
Senior Wows With Solo Finale Performance at PIR - Chaminade Silversword

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 74 (M)
Shares Float 50 (M)
% Held by Insiders 9.8 (%)
% Held by Institutions 55.8 (%)
Shares Short 1,620 (K)
Shares Short P.Month 1,490 (K)

Stock Financials

EPS -0.69
EPS Est Next Qtl -0.22
EPS Est This Year -0.86
EPS Est Next Year -0.95
Book Value (p.s.) 0.47
Profit Margin (%) -121.8
Operating Margin (%) -150.8
Return on Assets (ttm) -20.4
Return on Equity (ttm) -77.5
Qtrly Rev. Growth 32.4
Gross Profit (p.s.) -0.48
Sales Per Share 0.38
EBITDA (p.s.) -0.54
Qtrly Earnings Growth 0
Operating Cash Flow -58 (M)
Levered Free Cash Flow -33 (M)

Stock Valuations

PE Ratio -1.45
PEG Ratio 0
Price to Book value 2.06
Price to Sales 2.58
Price to Cash Flow -1.28

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.